SGD reduced the release of inflammatory factors IL-1β, IL-6 and TNF-α, upregulated COL2A1 and downregulated MMP-13 to alleviate degradation of ECM, and reduced the cartilage degeneration and progression of OA by reducing IL-17RB in articular cartilage. This evidence concerns the gene IL1B and specific granule deficiency.